Short answer
Bio-rad Laboratories Inc (BIO) filed its Q2 2018 10-Q quarterly report on Aug 9, 2018 for the quarter ended Jun 30, 2018.
Bio-rad Laboratories Inc Q2 2018 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q2 revenue $575.9M, up 14.1% YoY from $504.7M
- Gross margin 52.4% vs 54.2% YoY; SG&A margin 36.5% vs 42.1%
- Best segment: Life Science revenue $217.8M, up 21.4%; Clinical Diagnostics $354.0M, up 9.9%
- Cash, equivalents and short-term investments $818.2M; operating cash flow $118.2M vs $6.3M
- Headwinds: government spending constraints, sovereign payment risks, and facility closure costs; no updated guidance disclosed
Risk Factors
- EU General Data Protection Regulation, effective May 25, 2018, increased international compliance exposure
- Internal-control material weakness persisted, with remediation expected through December 31, 2018
- Tax Act implementation risk, provisional amounts subject to changes from regulatory guidance and further analysis
- ERP deployment disruptions, prior issues delayed manufacturing, logistics, invoicing and product shipments
- $440.5 million debt outstanding, alongside a $200.0 million revolving facility with covenant restrictions
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Bio-rad Laboratories Inc quarterly reports
- Q3 2019 10-QFiled Nov 1, 2019
- Q2 2019 10-QFiled Aug 6, 2019
- Q1 2019 10-QFiled May 10, 2019
- Q3 2018 10-QFiled Nov 5, 2018
- Q1 2018 10-QFiled May 10, 2018
- Q3 2017 10-QFiled Nov 9, 2017
- Q2 2017 10-QFiled Aug 7, 2017
- Q1 2017 10-QFiled May 9, 2017
- Q3 2016 10-QFiled Nov 2, 2016
- Q2 2016 10-QFiled Aug 5, 2016
- Q1 2016 10-QFiled May 6, 2016
- Q3 2015 10-QFiled Nov 5, 2015
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.